Form 4: EyePoint Pharmaceuticals Director Exercises Options and Sells Shares
SEC Form 4
David R. Guyer, a director at EyePoint Pharmaceuticals, exercised stock options and sold shares on May 14, 2024, according to a Form 4 filing with the SEC.
Summary
- On May 14, 2024, David R. Guyer, a director at EyePoint Pharmaceuticals, exercised stock options to acquire 6,525 shares at $3.26 and 3,250 shares at $3.50.
- Following the exercise of these options, Guyer sold 11,625 shares at a weighted average price of $12.649, with prices ranging from $12.44 to $12.83.
- After these transactions, Guyer directly owns 5,550 shares of common stock.
- Guyer also holds options to purchase 9,750 shares at $3.50 and 19,575 shares at $3.26.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. It doesn't indicate positive or negative outlook for the company.
Industry Context
This filing is a routine disclosure of insider transactions and provides insight into the actions of company leadership, which can be of interest to investors monitoring the company's performance and management's confidence.
Stakeholder Impact
- Shareholders may be interested in the transactions of company directors as an indicator of management's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 01/06/2024 | Date exercisable for some stock options |
| 02/23/2024 | Date exercisable for some stock options |
| 05/14/2024 | Date of transaction: exercise of stock options and sale of shares |
| 05/16/2024 | Date of signature for the Form 4 filing |
| 06/19/2033 | Expiration date for stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.